Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes by Edoardo Mannucci, Pier Paolo Mangia, Lorenzo Pradelli

“…Evidence from randomized controlled trials, observational and pharmacoeconomic studies suggest that SGLT2 inhibitors should be considered not only in patients with established cardiovascular disease and incipient nephropathy but also in earlier stages of T2D in order to prevent the first onset of cardiovascular and renal complications and contain the cost of illness.…”
Get full text

Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison by Jong Hyuk Lee

“…These mechanisms were: (1) essential OD, (2) pharmacoeconomic evaluation (PE) waiver OD, (3) weighted average price OD, and (4) PE OD. …”
Get full text

PILOT STUDY ON THE INCIDENCE OF BREAST CANCER AMONG THE POPULATION OF THE NORTH EAST REGION OF BULGARIA by Antoaneta Tsvetkova

“…Conclusion: Taking into consideration not only the efficiency but also the cost-effectiveness of available treatment strategies can lead to considerably better therapeutic outcomes. There is no pharmacoeconomic data analysis in Bulgaria. A further study of all direct and indirect costs is required in order to estimate the cost of premature death, reduced working capacity and disability.…”
Get full text

Terlipressina: profilo farmacologico clinico, terapeutico e farmacoeconomico nel trattamento delle varici esofagee by Lorenzo Pradelli

“…In this paper the main pharmacological and clinical features of terlipressin, a synthetic vasopressin analog, are outlined, as well as a frame for its pharmacoeconomical evaluation. Terlipressin is the only vasoactive drug that demonstrated survival benefits in cirrhotic patients with active variceal hemorrhage, even in those treated with endoscopic sclerotherapy, and is characterized by a favorable risk/benefit ratio. …”
Get full text

Denkbeeldige Wereld: The New Dutch Guidelines for Economic Evaluations in Healthcare by Paul C Langley

“…These Guidelines update and replace three previously published guidelines covering pharmacoeconomic evaluation, outcomes research and costing. …”
Get full text

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy. by Damiano Paolicelli, Sergio Iannazzo, Laura Santoni, Antonio Iaffaldano, Valentina Di Lecce, Alessia Manni, Vito Lavolpe, Carla Tortorella, Mariangela D'Onghia, Vita Direnzo, Elisa Puma, Maria Trojano

“…The cost increase related to the NAb+ status was €3,100 in the Italian societal perspective and €1,111 in the Italian NHS perspective.The results of this economic evaluation suggest the presence of an association between NAb+ status and increased costs for the management of RRMS in Italy. Further pharmacoeconomic research will be needed to confirm this first result.…”
Get full text

IMMUNOMODULATING THERAPY OF INFLUENZA AND ACUTE RESPIRATORY INFECTIONS IN HOSPITALS CHILDREN by E.A. Dondurey, L.V. Osidak, V.F. Sukhovetskaya, E.G. Golovachyova, V.V. Zarubayev, V.P. Drinevskiy, L.N. Gladchenko

“…</em><strong><em></em></strong></p><p><strong><em>Key words: children, influenza, acute respiratory infections, sodium desoxyribonucleate, treatment, pharmacoeconomical analysis.</em></strong><br /><span style="text-decoration: underline;"><em>(<em><em>Voprosy sovremennoi pediatrii — </em></em>Current Pediatrics. 2010;9(2):<em>45-53</em>)</em></span></p>…”
Get full text

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease by Paolo Gisondi, Davide Geat, Martina Maurelli, Luca Degli Esposti, Francesco Bellinato, Giampiero Girolomoni

“…Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per responder of secukinumab versus adalimumab in patients with psoriatic disease. …”
Get full text

Signalementen 2007/1 by - Redactiebureau

“…Pharmacoepidemiological and pharmacoeconomical aspects, Rijksuniversiteit Groningen, 15 september 2006, 160 p, ISBN 90 367 2717 0.   …”
Get full text

Traducción y adaptación transcultural del Constant-Murley Score al español de la Argentina by Diego Gómez, Tamara Dainotto, Daniel Moya, Juan Martín Patiño

“…Materiales y Métodos: La adaptación cultural se realizó siguiendo las etapas propuestas en la guía de la International Society of Pharmacoeconomic and Outcomes Research que establece las directrices para la traducción y adaptación cultural de medidas reportadas por los pacientes. …”
Get full text

The Use of Ozenoxacin in Pediatric Patients: Clinical Evidence, Efficacy and Safety by Giusy Davino, Tiziana D’Alvano, Susanna Esposito

“…Further studies with real-life analyses and pharmacoeconomic evaluation are needed to confirm its role as first-line and second-line therapy in children with impetigo.…”
Get full text

Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast by A V Rudakova, D G Tolkacheva, O N Gavrilova, A S Vaganov

“…Empegfilgrastim has the same therapeutic efficacy, as well as pharmacoeconomic advantages in comparison with non-pegylated filgrastim, reducing impacts on a budget and can be recommended to be used in clinical practice.…”
Get full text

Ocrelizumab in treatment of primary-progressive multiple sclerosis: systematic review by D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, E. M. Olyushina, K. I. Polyakova, A. G. Fisun, M. G. Grinin, K. A. Kokushkin

“…To analyze the efficacy, safety and pharmacoeconomic indicators of ocrelizumab in adult patients with primary progressive multiple sclerosis (PPMS). …”
Get full text

The impact of LABA+ICS fixed combinations on morbidity and economic burden of COPD in Italy: a six-year observational study by Roberto Dal Negro, Luca Bonadiman, Silvia Tognella, Claudio Micheletto, Paola Turco

“…Background: In Italy, chronic obstructive pulmonary disease (COPD) has progressively received increasing attention in the last decade, and its impact has been investigated extensively in both clinical and pharmacoeconomic terms. Methods: In 2004, the national health authorities stated the appropriateness of long-acting β 2 agonists (LABA) and inhaled corticosteroids (ICS) fixed combinations for treating COPD, even though this pharmaceutical option was limited to the severe and very severe stages of the disease (forced expiratory volume in one second [FEV 1 ] <50% predicted). …”
Get full text

Economic aspects of the fixed combinations of lipid lowering medicines in group risks patients by M. V. Zhuravleva, M. Yu. Frolov, E. A. Luchinin, K. A. Kokushkin, E. D. Laryushkina, T. R. Kameneva, E. V. Kuznetsova

“…Combination of statin + ezetemib is an effective option of a medical technology for this purpose. Pharmacoeconomic analysis of rosuvastatin and ezetemib fixed combination (FC) has been performed in this work in comparison with free combination (FrC) of these drugs.Materials and methods. …”
Get full text

COST OF ILLNESS FOR CHRONIC KIDNEY DISEASE TREATMENT WITH HEMODIALYSIS IN YOGYAKARTA by Ingenida Hadning, Muhammad Heyqal Wirakarsa, Muhamad Rinaldhi Tandah Tandah

“…This study aimed to determine the cost of illness of CKD patients undergoing hemodialysis, as well as to find out the comparison of real costs with INA-CBG’s rates. This was a pharmacoeconomic research, used the cost of illness method according to a societal perspective. …”
Get full text

Analysis of the pneumonia morbidity in children in order to optimize pharmaceutical aid by V. V. Trokhimchuk, O. I. Belyaeva

“…It is necessary to conduct pharmacoeconomic analysis of rational choice of drugs and rational use of healthcare resources.…”
Get full text

Pharmaceutical Drug Pricing In Malaysia: An Assessment Of Perception, Mechanisms, And International Comparisons by Shukeri, Mohammad Amirul Ashraf Mohammad

“…The study was structured into seven workstreams, ranging from current policies and strategies, comparison with other countries, perception of the public on the drug price, policy analysis and pharmacoeconomic analysis. Workstream One, Two, Three, Five and Six are qualitative studies and Workstream Five and Seven are quantitative studies. …”
Get full text

Early oral switch to combined cefixime therapy for management of osteoarticular infections in pediatric sickle cell disease patients: A descriptive analysis by Yahya A. Mohzari, Renad Alshuraim, Syed Mohammed Basheeruddin Asdaq, Fahad Aljobair, Ahmed Alrashed, Yazed Saleh Alsowaida, Amnah Alamer, Manea Fares Al Munjem, Mohammed I. Al Musawa, Muhannad Hatata, Meshal A. Alzaaqi, Aljawharah Binrokan, Saleh Ahmad Alajlan, Ivo Abraham, Ahmad Alamer

Get full text

Ademetionine treatment cost analysis of patients with intrahepatic cholestasis and non-alcoholic fatty disease by M. V. Zhuravleva, G. V. Kukushkin, E. V. Luchinina, T. V. Shelekhova, T. R. Kameneva, E. V. Kuznetsova, E. A. Luchinin

“…Because of the study, the average costs for treating patients with NAFLD and ITH were calculated, which can later be used to conduct other types of pharmacoeconomic analysis.…”
Get full text